GLIA Diagnostics Pty Ltd

GLIA Diagnostics (GLIA) is committed to advancing the diagnosis and prognosis of traumatic brain injury (TBI), with a specific focus on mild TBI (mTBI)/concussion, to improve patient outcomes. Our mission is to enhance understanding of brain-related injury through rigorous research and education, and to validate a suite of biomarkers that, when integrated with a dedicated point-of-care (POC) device, will provide a definitive diagnostic and prognostic tool. Our team comprises experienced professionals working in close collaboration with leading medical and scientific experts globally. Through robust clinical trials across diverse cohorts, we aim to validate biomarkers alongside complementary diagnostic modalities to establish a reliable, objective solution for the identification of TBI, particularly in cases of concussion. With deep expertise in biomedicine, diagnostics, translational research, and device development, GLIA is uniquely positioned to drive meaningful progress in this critical field. We envision GLIA as a central hub, fostering collaboration among synergistic partners across Australasia and internationally. We firmly believe that the future of TBI diagnostics lies in the integration of biomarker panels with multiple diagnostic modalities to enable precise, real-time decision-making in both clinical and field settings.